Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market

Fineline Cube Mar 26, 2026
Company Deals

MSD to Acquire Terns Pharmaceuticals for $6.7 Billion – TERN-701 BCR::ABL1 Inhibitor Targets Chronic Myeloid Leukemia

Fineline Cube Mar 26, 2026
Company Deals

Daiichi Sankyo Partners with Tempus AI – Foundation Models Target ADC Biomarker Discovery and Patient Stratification

Fineline Cube Mar 26, 2026
Company Deals

Thermo Fisher Partners with SHL Medical – Autoinjector Manufacturing Expansion Targets U.S. Drug-Device Combination Market

Fineline Cube Mar 26, 2026
Company Deals

Insilico Medicine Expands AI Collaboration with Tenacia Bio – $94.75M Deal Targets CNS Drug Discovery with Blood-Brain Barrier Penetration

Fineline Cube Mar 26, 2026
Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026
Company Drug

Novo Nordisk’s Awiqli Wins FDA Approval – World’s First Once-Weekly Basal Insulin for Type 2 Diabetes

Fineline Cube Mar 27, 2026
Company Drug

Hengrui Pharma’s HRS9531 Wins NMPA Approval for Cardiovascular Outcomes Trial – Dual GIPR/GLP-1R Agonist Targets MACE Reduction

Fineline Cube Mar 27, 2026
Company Drug

Mabwell Bioscience Receives NMPA Approval for 6MW3511 Clinical Trial in Solid Tumors

Fineline Cube Aug 24, 2022

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that the National Medical Products Administration...

Company Drug

Bio-Thera Solutions Receives NMPA Approval for BAT8008 Clinical Trial in Solid Tumors

Fineline Cube Aug 24, 2022

Bio-Thera Solutions (SHA: 688177), a Guangzhou-based biotech firm, has received approval from the National Medical...

Company Drug

BeiGene’s Tislelizumab Receives 11th NMPA Filing for First-Line Esophageal Cancer

Fineline Cube Aug 24, 2022

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced that the National Medical Products Administration (NMPA)...

Company Drug

Innovent Biologics Doses First Patient in Australia Trial for PD-1/IL-2 Bispecific Antibody IBI363

Fineline Cube Aug 24, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) announced that the first patient has been dosed in...

Company Deals

Lee’s Pharma Expands Global Rights to Windtree’s KL4 Surfactant Products

Fineline Cube Aug 24, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has expanded its licensing agreement with US-based Windtree...

Company Deals

Genetron Holdings Receives Buyout Offer from CEO Wang Sizhen at USD 1.36 per ADS

Fineline Cube Aug 24, 2022

Beijing-based precision oncology firm Genetron Holdings Ltd announced receipt of a buyout and take-private offer...

Drug Legal / IP

Supreme People’s Court Rules Against Chugai in China’s First Patent Linkage Case

Fineline Cube Aug 24, 2022

China’s Supreme People’s Court has delivered its verdict in the nation’s first patent linkage dispute,...

Company

Ascletis Pharma’s H1 2022 Revenue Rises 4.8% on R&D and Product Sales Growth

Fineline Cube Aug 23, 2022

Ascletis Pharma Inc. (HKG: 1672) reported RMB 38.2 million (USD 5.96 million) in revenue for...

Company Drug

Viatris Pharmaceuticals’ HIV/AIDS Drug Prioritized for CDE Review

Fineline Cube Aug 23, 2022

The Center for Drug Evaluation (CDE) has indicated that Viatris Pharmaceuticals Co., Ltd’s efavirenz/lamivudine/tenofovir is...

Company Deals

Hansoh Pharma Licenses GHDDI’s GDI-4405 for Global Development in COVID-19

Fineline Cube Aug 23, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced a licensing agreement with the Global...

Company Drug

Anhui Anke’s HK010 Bispecific Antibody Receives NMPA Review for Cancer Trials

Fineline Cube Aug 23, 2022

Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that the National Medical Products Administration...

Company Deals

China-Based Firms Form Partnership to Advance Cell and Gene Therapy Ecosystem

Fineline Cube Aug 23, 2022

Six China-based companies—Porton Advanced Solutions Ltd, Shanghai Sequanta Biological Technology Co., Ltd, QuaCell Biotechnology Co.,...

Company Deals

BIOPSEE Series A+ Financing Confocal Microendoscope

Fineline Cube Aug 23, 2022

BIOPSEE, a Hubei-based microendoscope specialist, has raised tens of millions of renminbi in a Series...

Company Drug

CSPC Pharmaceutical’s DBPR108 Hits Endpoints in Type 2 Diabetes Trials

Fineline Cube Aug 23, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its Category 1 drug DBPR108 has...

Company Drug

Shanghai Pharmaceuticals Gets NMPA Approval for B013 in Triple-Negative Breast Cancer

Fineline Cube Aug 23, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) has received approval from the National Medical Products Administration...

Company Drug

Scitop Bio-tech’s KEX02 Live Bacteria Therapy Gets FDA IND Approval for NSCLC

Fineline Cube Aug 23, 2022

Beijing Scitop Bio-tech Co., Ltd (SHE: 300858) announced that the US Food and Drug Administration...

Company Deals

Sanyou Biopharmaceuticals and KangaBio Ink Licensing Deal for Antibody Drug Candidate

Fineline Cube Aug 22, 2022

Shanghai-based Sanyou Biopharmaceuticals Co., Ltd and KangaBio have entered into a licensing agreement, granting Kanga...

Company

InnoCare Pharma’s 2022 Interim Report Shows Strong Revenue Growth Driven by Orelabrutinib Sales

Fineline Cube Aug 22, 2022

China-based InnoCare Pharma (HKG: 9969) announced its 2022 interim financial results, reporting total revenues of...

Company Deals

Porton Biologics Completes RMB 520M Series B to Expand Gene and Cell Therapy CDMO Platform

Fineline Cube Aug 22, 2022

Suzhou Porton Biologics Ltd, a China-based contract development and manufacturing organization (CDMO), announced the completion...

Company Drug

Nuance Pharma Gets NMPA Green Light for Ensifentrine COPD Trials in China

Fineline Cube Aug 22, 2022

China-based Nuance Pharma has secured approval from the National Medical Products Administration (NMPA) to conduct...

Posts pagination

1 … 609 610 611 … 642

Recent updates

  • Novo Nordisk’s Awiqli Wins FDA Approval – World’s First Once-Weekly Basal Insulin for Type 2 Diabetes
  • Hengrui Pharma’s HRS9531 Wins NMPA Approval for Cardiovascular Outcomes Trial – Dual GIPR/GLP-1R Agonist Targets MACE Reduction
  • CStone Pharma 2025 Revenue RMB 269.6M Down 34% – NRDL Price Adjustment Hits Pralsetinib, Licensing Fees Decline
  • Chengdu Kanghong’s KHN922 Wins NMPA Approval – Dual-Payload HER3 ADC Targets Advanced Solid Tumors with Anti-Resistance Mechanism
  • Huadong Medicine’s HDM2024 Wins NMPA Approval – EGFR/HER3 Bispecific ADC Targets Advanced Solid Tumors
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novo Nordisk’s Awiqli Wins FDA Approval – World’s First Once-Weekly Basal Insulin for Type 2 Diabetes

Company Drug

Hengrui Pharma’s HRS9531 Wins NMPA Approval for Cardiovascular Outcomes Trial – Dual GIPR/GLP-1R Agonist Targets MACE Reduction

Company

CStone Pharma 2025 Revenue RMB 269.6M Down 34% – NRDL Price Adjustment Hits Pralsetinib, Licensing Fees Decline

Company Drug

Chengdu Kanghong’s KHN922 Wins NMPA Approval – Dual-Payload HER3 ADC Targets Advanced Solid Tumors with Anti-Resistance Mechanism

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.